CIK: 0001799883
Total reported value
$360.2M
Reporting period: 2026-03-31 · Number of holdings: 20
5AM Venture Management, LLC disclosed 20 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $360.2M and a quarterly turnover rate of 46.0%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "0-9"
Sector classification currently covers about 0% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add ERAS
-35.5% $36.3M
Trim CAMP
0.0% -$10.1M
Add TYRA
0.0% $12.4M
Trim EYPT
0.0% -$5.6M
Add 260
0.0% $8.5M
Add TECX
0.0% $6.1M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ERAS | Erasca INC | Stock-Other | 15.66% | +9.34% | -35.51% | |
| 2 | TRDA | Entrada Therapeutics INC | Stock-Other | 14.21% | +1.10% | — | |
| 3 | TYRA | Tyra Biosciences INC | Stock-Other | 10.94% | +2.43% | — | |
| 4 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 7.19% | -4.12% | — | |
| 5 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 6.41% | +1.84% | — | |
| 6 | PHVS | Pharvaris N.V. | Stock-Other | 6.26% | -0.70% | — | |
| 7 | MPLT | Maplight Therapeutics INC | Stock-Other | 5.36% | +0.11% | — | |
| 8 | TECX | Tectonic Therapeutic INC | Stock-Other | 5.21% | +1.23% | — | |
| 9 | CLDX | Celldex Therapeutics INC | Stock-Other | 4.38% | +0.13% | — | |
| 10 | ARTV | Artiva Biotherapeutics INC | Stock-Other | 4.21% | +1.04% | — | |
| 11 | EYPT | Eyepoint INC | Stock-Other | 3.76% | -2.27% | — | |
| 12 | SRZN | Surrozen INC | Stock-Other | 3.13% | +0.38% | — | |
| 13 | ZNTL | Zentalis Pharmaceuticals INC | Stock-Other | 2.56% | +0.88% | — | |
| 14 | GHRS | GH Research PLC | Stock-Other | 2.24% | -0.05% | — | |
| 15 | TARA | Protara Therapeutic INC | Stock-Other | 1.98% | -0.32% | — | |
| 16 | BHVN | Biohaven Ltd. | Stock-Other | 1.74% | -0.88% | — | |
| 17 | ALXO | Alx Oncology Holdings INC | Stock-Other | 1.70% | +1.70% | NEW | |
| 18 | SKYE | Skye Bioscience INC | Stock-Other | 1.65% | -0.63% | — | |
| 19 | RLYB | Rallybio CORP | Stock-Other | 0.73% | +0.73% | NEW | |
| 20 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.70% | -0.21% | — |
Performance for Q3 2026
+7.9%
Performance Last 4 Quarters
+24.5%
Based on 86% of reported portfolio value with available pricing
Not enough sector-mapped data yet
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 20 | $360.2M | 46 | |
| 2025-12-31 | 21 | $318.1M | 60 | |
| 2025-09-30 | 25 | $273.0M | 54 | |
| 2025-06-30 | 29 | $260.1M | 0 | |
| 2025-03-31 | 31 | $264.4M | 100 | |
| 2024-12-31 | 31 | $419.1M | 0 | |
| 2024-09-30 | 28 | $484.0M | 0 | |
| 2024-06-30 | 28 | $447.1M | 0 | |
| 2024-03-31 | 26 | $446.6M | 0 | |
| 2023-12-31 | 25 | $377.0M | 0 | |
| 2023-09-30 | 26 | $347.5M | 0 | |
| 2023-06-30 | 24 | $401.4M | 0 | |
| 2023-03-31 | 24 | $391.0M | 0 | |
| 2022-12-31 | 21 | $372.1M | 0 | |
| 2022-09-30 | 21 | $522.0M | 0 | |
| 2022-06-30 | 21 | $404.2M | 0 | |
| 2022-03-31 | 19 | $457.8M | 0 | |
| 2021-12-31 | 17 | $532.8M | 0 | |
| 2021-09-30 | 16 | $492.5M | 0 | |
| 2021-06-30 | 12 | $397.3M | 51 | |
| 2021-03-31 | 11 | $555.4M | 87 | |
| 2020-12-31 | 10 | $296.9M | 39 | |
| 2020-09-30 | 9 | $380.3M | 19 | |
| 2020-06-30 | 9 | $456.6M | 47 | |
| 2020-03-31 | 8 | $323.0M | 39 | |
| 2019-12-31 | 9 | $464.8M | 0 |
5AM Venture Management, LLC's most significant position changes for 2026-03-31: Sold out: Viridian Therapeutics INC (VRDN); Sold out: Enliven Therapeutics INC (ELVN); New buy: Alx Oncology Holdings INC (ALXO); New buy: Rallybio CORP (RLYB); Sold out: Rallybio CORP.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ERAS | Erasca INC | +9.3% | -35.51% | Trim |
| 2 | TYRA | Tyra Biosciences INC | +2.4% | — | Unchanged |
| 3 | 260 | Centessa Pharmaceuticals-adr | +1.8% | — | Unchanged |
| 4 | TECX | Tectonic Therapeutic INC | +1.2% | — | Unchanged |
| 5 | TRDA | Entrada Therapeutics INC | +1.1% | — | Unchanged |
| 6 | ARTV | Artiva Biotherapeutics INC | +1% | — | Unchanged |
| 7 | ZNTL | Zentalis Pharmaceuticals INC | +0.9% | — | Unchanged |
| 8 | SRZN | Surrozen INC | +0.4% | — | Unchanged |
| 9 | CLDX | Celldex Therapeutics INC | +0.1% | — | Unchanged |
| 10 | MPLT | Maplight Therapeutics INC | +0.1% | — | Unchanged |
| 11 | GHRS | GH Research PLC | -0.1% | — | Unchanged |
| 12 | SLN | Silence Therapeutics Plc-adr | -0.2% | — | Unchanged |
| 13 | TARA | Protara Therapeutic INC | -0.3% | — | Unchanged |
| 14 | SKYE | Skye Bioscience INC | -0.6% | — | Unchanged |
| 15 | PHVS | Pharvaris N.V. | -0.7% | — | Unchanged |
| 16 | BHVN | Biohaven Ltd. | -0.9% | — | Unchanged |
| 17 | EYPT | Eyepoint INC | -2.3% | — | Unchanged |
| 18 | CAMP | Camp4 Therapeutics CORP | -4.1% | — | Unchanged |
| 19 | VRDN | Viridian Therapeutics INC | — | EXIT | Sold out |
| 20 | ELVN | Enliven Therapeutics INC | — | EXIT | Sold out |
| 21 | ALXO | Alx Oncology Holdings INC | — | NEW | New buy |
| 22 | RLYB | Rallybio CORP | — | NEW | New buy |
| 23 | ✓ | Rallybio CORP | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-03 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-16 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-05 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-04-29 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-05 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001535521
Total reported value
$360.1M
133 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001821549
Total reported value
$360.4M
106 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001904825
Total reported value
$360.0M
45 stks
2026-03-31
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0001201001
Total reported value
$100.9M
5 stks
2026-03-31
1 of the top 5 holdings overlap, including Camp4 Therapeutics CORP
CIK 0001224962
Total reported value
$5.1B
94 stks
2026-03-31
1 of the top 5 holdings overlap, including Centessa Pharmaceuticals-adr
CIK 0001263048
Total reported value
$44.5M
4 stks
2025-09-30
Stale — no recent filing
1 of the top 5 holdings overlap, including Entrada Therapeutics INC